Overview
IMNM market data
Price History
IMNM price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for IMNM. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Wedbush Reiterates Outperform on Immunome, Maintains $31 Price TargetBenzinga · Jul 21, 2026, 1:33 PM
Immunome Announces First Patient Dosed In Phase 1 IM-3050 Trial To Treat FAP-Expressing Advanced Solid TumorsBenzinga · Jul 20, 2026, 11:34 AM
Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA ReviewBenzinga · Jul 8, 2026, 5:25 PM
Immunome's New Drug Application For Desmoid Tumors Treatment Accepted By FDA, April 28, 2027 Assigned As Prescription Drug User Fee Act Target Action DateBenzinga · Jul 8, 2026, 11:35 AM
Immunome Does First Participant In Its Phase 1 IM-1617 Study To Treat Solid TumorsBenzinga · Jun 11, 2026, 11:32 AM
Truist Securities Maintains Buy on Immunome, Raises Price Target to $37Benzinga · May 28, 2026, 4:04 PM
Barclays Initiates Coverage On Immunome with Overweight Rating, Announces Price Target of $36Benzinga · May 28, 2026, 1:45 PM
HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price TargetBenzinga · May 13, 2026, 11:11 AM
Immunome Q1 EPS $(0.48) Beats $(0.57) EstimateBenzinga · May 12, 2026, 9:10 PM